KUR-002

KUR-002 is an investigational small-molecule neuropsychiatric drug originally discovered at Columbia University and being developed by Kures (now part of atai Life Sciences) for the treatment of depressive disorders, particularly specific subsets of depression. Public information indicates it is a preclinical small molecule with a novel mechanism of action distinct from conventional antidepressants, but the precise molecular target and pharmacology have not been disclosed. The program is positioned as a differentiated approach to mood disorders within atai’s portfolio, complementing other assets such as KUR-101 for opioid-related indications.